At a higher concentration of the drug (10 mg kg−1), the group receiving Dex-SA-CDDP-LHRH treatment exhibited greater regression in their tumor volumes (tumor regression rates of 70%) than untreated formulation, without any systemic toxicity [158]. Here, GNRH1 is linked to neoplasm.